Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

From the death of folk music star Peter Yarrow of Peter, Paul and Mary to good news from broadcasting legend Dick Vitale, ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...

Pfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer.

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

January is firefighter cancer awareness month, and firefighters have a nine percent chance more than the general public to ...

An AI system developed to predict a patient's response to immunotherapy could help "democratize" access to the pricey drugs ...

Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 ...

Prostate cancer is usually treated with surgery and radiation therapy, but these can have drastic side effects. A new ...

About 70 per cent of people over the age of 70 have nocturia - the need to go to the toilet in the middle of the night. But ...